Preparation and application of hadv chimeric vaccine with influenza virus as carrier

A technology of influenza virus and chimeric vaccine, applied in the direction of virus/bacteriophage, virus, antiviral agent, etc., can solve the problems of not ideal immunization route, low titer of neutralizing antibody, inconvenience, etc.

Active Publication Date: 2017-04-26
THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

As early as the 1960s, the United States had used enteric-coated live attenuated adenovirus vaccines to conduct immunization experiments on adults in boot camps, and found that it could reduce the fever symptoms caused by adenoviruses by 90%. Clinical testing found that the neutralizing antibody titer induced by this live vaccine was very low
In the 1970s, adenovirus enteric-coated live vaccine was used for immunization, and serum IgM, IgG, and IgA were found to be elevated, but no corresponding IgA antibodies were found in nasal secretions
For HAdV vaccines for respiratory mucosal infection, injection vaccination is not ideal and inconvenient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation and application of hadv chimeric vaccine with influenza virus as carrier
  • Preparation and application of hadv chimeric vaccine with influenza virus as carrier
  • Preparation and application of hadv chimeric vaccine with influenza virus as carrier

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0082] Experimental example 1, the preparation of the HAdV chimeric vaccine rFLU-HAdV / NS1 of the chimeric HAdV-Hexon-L1 / L2 dominant antigen epitope of the influenza virus as the carrier

[0083] 1. The dominant antigenic epitope sequence of Hexon-L1 / L2 (HAdV-Hexon-L1 / L2) in HAdV types 3 and 7 is shown in SEQID No.1, which has been verified by animal experiments and clinical patient serum, and is in line with the next experiment Require.

[0084] 2. Construction of recombinant plasmid pHexon-L1 / L2-NS1

[0085] Using the NS1 gene fragment of the cold-adapted and attenuated influenza virus strain A / AA / 6 / 60 as the target for inserting the dominant epitope gene of HAdV-Hexon-L1 / L2, the recombinant plasmid pHexon-L1 / L2-NS1, the specific policy is as follows figure 1 As shown in A.

[0086] Specifically, the HAdV-Hexon-L1 / L2 dominant antigenic epitope gene is inserted into the coding gene of the first 125 amino acids of the NS1 gene open reading frame (ORF) of the cold-adapted an...

Embodiment 3

[0137] Embodiment 3, the preparation of the HAdV chimeric vaccine rFLU-HAdV / NA of the chimeric HAdV-Hexon-L1 / L2 dominant epitope of the influenza virus as the carrier

[0138] 1. The dominant epitope sequence of HAdV-Hexon-L1 / L2 in HAdV types 3 and 7 is shown in SEQ ID No.1, verified according to the method of step 1 of Example 1, and meets the requirements of the next experiment.

[0139] 2. Construction of recombinant plasmid pHexon-L1 / L2-NA

[0140] Using the NA gene fragment of A / California / 07 / 2009 (H1N1) as the target for inserting the dominant epitope gene of HAdV-Hexon-L1 / L2, the recombinant plasmid pHexon-L1 / L2-NA was constructed by molecular biology methods, specifically Strategies such as figure 1 C shows.

[0141] Specifically, the HAdV-Hexon-L1 / L2 dominant antigen epitope gene was inserted into the first 183 nucleotides and the last nucleotide of the NA gene open reading frame (ORF) of the influenza virus strain H1N1 subtype A / California / 07 / 2009 that year. Betwe...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses the preparation and application of an HAdV chimeric vaccine with influenza virus as a carrier. The present invention discloses the DNA molecule shown in SEQ ID No.1. The HAdV chimeric vaccine disclosed by the invention can cover the HAdV infectious disease pathogen, protect more people from the harm of influenza virus and HAdV, and lay a foundation for realizing "one vaccine with two uses" or "one vaccine with multiple uses".

Description

technical field [0001] The invention relates to the preparation and application of an HAdV chimeric vaccine with influenza virus as a carrier. Background technique [0002] Respiratory tract infectious diseases are still one of the main causes of death in the world, and adenovirus (Adenovirus, AdV) and influenza virus are important respiratory pathogens. As we all know, adenovirus is widely distributed in nature and is one of the common pathogens of children's respiratory diseases. About 5%-10% of acute upper respiratory tract infections in children under 3 years old are caused by adenovirus. From the clinical survey results of hospitalized children in northern and southern my country, it is confirmed that adenovirus types 3 and 7 are the main pathogens of adenovirus pneumonia, and the lower respiratory tract infections caused by them account for 50% of all adenovirus infections. Adenoviruses, due to their multiple types and wide range of pathogenicity, pose a serious thre...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C12N15/11C12N7/01A61K39/145A61K39/235A61P31/16A61P31/20
CPCA61K39/12A61K2039/5254A61K2039/5256A61P31/16A61P31/20C12N2710/10034
Inventor 杨鹏辉王希良张绍庚刘娜段跃强张培瑞李志伟王兆海
Owner THE FIFTH MEDICAL CENT OF CHINESE PLA GENERAL HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap